ENETF yields 400000.00% · JNJ yields 2.13%● Live data
📍 ENETF pulled ahead of the other in Year 1
Combined, ENETF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ENETF + JNJ for your $10,000?
Ethernity Networks Ltd. provides technology solutions for telecom, mobile, security, and data center markets in Asia, Europe, Israel, and the United States. The company develops and delivers data processing technology and solutions for carrier Ethernet switching, including broadband access, mobile backhaul, carrier Ethernet demarcation, and data centers. It provides ENET flow processors for telco/cloud network; ACE-NIC40 SmartNIC, an open flow enabled software acceleration NIC; ACE-NIC40 SmartNIC, an open flow enabled software acceleration NIC; ACE-NIC50 SmartNIC, which offers 10/25G Ethernet connectivity and field-programmable gate array (FPGA) acceleration; ACE-NIC100 SmartNIC that provides flexible 10/25/40/100G Ethernet connectivity and programmable FPGA acceleration; ENET UEP-60, a programmable routing appliance for 5G, OpenRAN, and Network Edge; and ACE-NIC100 SmartNIC that provides flexible 10/25/40G/100G Ethernet connectivity and programmable FPGA acceleration. The company also offers ENET network appliances, such as ENET UEP-20 universal edge platform and ENET UEP-60 universal edge platform. In addition, it provides FPGA based networking and security solutions to telco/cloud equipment manufacturers and system integrators. The company was formerly known as Neracore Ltd. and changed its name to Ethernity Networks Ltd. in August 2004. Ethernity Networks Ltd. was incorporated in 2003 and is headquartered in Airport City, Israel.
Full ENETF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.